Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tritanrix-HepB low thio · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tritanrix™-HepB low thio / | BIOLOGICAL | One dose as intramuscular injection at 6, 10 and 14 weeks of age. |
| Hib 2.5 | BIOLOGICAL | One dose as intramuscular injection at 6, 10 and 14 weeks of age. |
| Tritanrix™-HepB | BIOLOGICAL | One dose as intramuscular injection at 6, 10 and 14 weeks of age. |
| Hiberix™ | BIOLOGICAL | One dose as intramuscular injection at 6, 10 and 14 weeks of age. |
| Unconjugated Hib vaccine (plain PRP) | BIOLOGICAL | One dose as intramuscular injection at 10 months of age |
Inclusion Criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including, 6 and 8 weeks of age at the time of the first vaccination. * Written inform...
Tritanrix-HepB low thio is an investigational vaccine developed by GSK plc for Haemophilus influenzae type b, an infectious disease. It was studied in a Phase 2 clinical trial in the Philippines. The vaccine is not approved and remains in clinical development.
Tritanrix-HepB low thio is being studied for Haemophilus influenzae type b, an infectious disease. The Phase 2 trial enrolled healthy volunteers from 6 weeks of age in the Philippines. It is an investigational product and has not been approved for use.
Tritanrix-HepB low thio is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 2 trial of the vaccine. The product is an investigational candidate and is not approved.
Tritanrix-HepB low thio is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The vaccine is investigational and has not been approved for any indication.
Tritanrix-HepB low thio was studied in one completed Phase 2 trial, NCT01061541, titled Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix-HepB/Hiberix. The randomized, double-blind, active-controlled trial enrolled 192 healthy volunteers in the Philippines.